This study measures hexose monophosphate (HMP) shunt activity, glycolytic rate, and glucose transport in PMN and lymphocytes of patients with glycogen storage disease (GSD) type lb as compared with controls and with GSD Ia patients. HMP shunt activity and glycolysis were significantly lower in intact PMN cells of GSD Tb patients as compared with GSD Ia patients and with controls. These activities were above normal levels in disrupted GSD lb PMN. HMP shunt activity and glycolytic rates in lymphocytes were similar in all three groups studied. The rate of 2-deoxyglucose transport into GSD Tb PMN was 30% of that into cells of normal controls. In GSD Tb lymphocytes or in GSD Ia PMN and lymphocytes transport was normal. The striking limitation of glucose transport across the cell membrane of the PMN of GSD Tb patients may account for the impairment of leukocyte function that is characteristic of GSD Tb, but not found in GSD Ia patients.
Introduction
Glycogen storage disease (GSD)' type I is a metabolic disease caused by a defect in the activity of glucose-6-phosphatase (D-glucose-6-phosphate phosphohydrolase, EC 3.1.3.9) (G6Pase), normally present in liver, kidney, and intestinal mucosa cells (1, 2) .
Hepatic glucose-6-phosphatase is part of the multicomponent system of the endoplasmic reticulum (3) . In 1975, Arion postulated that at least three components of the endoplasmic reticulum participate in the process of glucose-6-phosphate (G6P) hydrolysis: (a) a G6P specific translocase that shuttles G6P across the membrane; (b) a relatively nonspecific phosphohydrolase located on the luminal surface ofthe membrane; and (c) a translocase which mediates phosphate efflux out of the cisternae of the endoplasmic reticulum (4, 5) .
Three groups of patients with GSD I have been identified:
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(a) GSD Ia patients, whose liver specimens lack the enzyme G6Pase (1); (b) GSD lb patients, whose translocase for G6P in the microsomal membrane is defective (5, 6) ; and (c) GSD Ic patients, who lack the translocase for phosphate (7) .
Patients with GSD lb suffer from recurrent bacterial infections related to neutropenia and impairment of neutrophil functions (8, 9) .
In most patients with GSD Tb, defects in random and direct cell migration (10, 11) , bactericidal activity (12) , phagocytosis (13) , superoxide anion production (1 1, 14) , and hexose monophosphate (HMP) activity (14) have been described. Since these functions all depend on an adequate supply of energy and NADP, we studied HMP shunt activity, glycolytic activity, ATP concentration, and glucose transport in PMN ofthree GSD Tb patients as compared with controls.
Methods

Patients
GSD was diagnosed on liver biopsies: GSD Ia by the absence of G6Pase activity, and GSD lb by a high latency, i.e., low activity of G6Pase in fresh homogenates and normal activity in disrupted microsomes (15). The three GSD lb patients suffered from numerous infections. The clinical and therapeutic data of the three GSD lb patients and the one GSD Ia patient are summarized in Table I . There were no differences in the therapeutic management and the nutritional support of the patients. Studies of PMN were performed on preparations with Triton-X100. HMP shunt activity was measured as described for intact cells, in the presence of 0.75 mM NADP and 0.75 mM ATP.
Glycolytic activity
In intact cells. Glycolytic activity was measured as described earlier (17) : leukocytes (1.5-3 X 106) were incubated at 37°C in a medium containing 100 mM Hepes buffer, 5 mM KCl, 80 mM NaCl, 1.2 mM MgSO4, 2.5 mM CaC12, 0.2 mM NaH2PO4, and 2.5 mM glucose, pH 7.6, in a final volume of 0.5 ml. Lactate production was determined as described previously (18) . In disrupted cells. Cells (1.5-3 X 106) were suspended in KRP containing 1% Triton X-100, 5 mM glucose, 1 mM ATP, and 0.7 mM NAD. Lactate production was measured as in intact cells.
Glucose transport
Uptake of 2-deoxyglucose was measured as previously described (19) . 2 X 106 purified PMN or lymphocytes-monocytes were suspended in 1 ml KRP containing 5 MCi/ml [1-3H]2-deoxyglucose at concentrations indicated in the legends. Suspensions were incubated at 37°C, and uptake was stopped at various time intervals by adding 1 ml cold 0.9% NaCI. The samples were centrifuged at 3,000 g for 3 min and the pellets were washed twice with 2 ml cold 0.9% NaCl and centrifuged. The final pellet was dissolved in 0.5 ml water, and after repeated freeze-thawing procedures, samples were taken for determination of radioactivity and protein.
Phosphorylation of2-deoxyglucose PMNs (I X 106) were incubated at 37°C in a shaking bath for different lengths of time in a final volume of 60 Ml containing I mmol/liter [l-3H]-2-deoxyglucose (0.2 MCi). The reaction was stopped by chilling in ice. The samples were centrifuged at 3,000 g for 2 min. The pellets were then washed three times in 0.9% wt/vol NaCl. The final pellets were suspended in 1 ml water and boiled for 5 min in a water bath. Subsequently, denatured protein was removed by centrifugation at 27,000 g for 10 min. The entire supernatant was applied to a small column of Dowex-l-CI-resin (10 cm X 1 cm) as previously described (19) . The column was washed with 30 ml of H20 to elute free 2-deoxyglucose, and fractions of 0.5 ml were collected. The column was then washed with 30 ml of 0.5 mol/liter HO to remove deoxyglucose-6-phosphate, and 0.5-ml fractions were collected. Each fraction was added to 5 ml Instagel and the radioactivity was measured in a liquid scintillation spectrometer. at 4°C, and pellets and supernatants were counted for radioactivity.
ATP concentration in the PMN was measured by the luciferin-luciferase method (21). Glycogen concentration in the PMN was measured after alcohol precipitation as previously described (22). Activities of hexokinase, G6P, and 6-phosphogluconate dehydrogenases were measured as described previously (18 
Results
HMP shunt activity in intact PMN of GSD lb patients (Fig. 1  B) was about one-third of that found in PMN of normal controls ( Fig. 1 A) patients ( Fig. 1 B' ) was higher than in those from controls and one GSD la patient (Fig. 1, A' and C'). Table II shows that the activities of the rate-limiting enzymes of glycolysis and the HMP shunt-hexokinase, G6P, and 6-phosphogluconate dehydrogenase-were normal. During infections, HMP shunt activity in PMN of GSD lb patients increased to the level found in cells from controls (Table III) . HMP shunt activity in PMN ofpatients suffering from recurrent familiar neutropenia was found to be within the normal range both in intact and in disrupted cells (Table III) . In lymphocytes of GSD lb, GSD la, and controls, HMP shunt activity was in the same range in both intact and disrupted cells (Fig. 2) . Glycolytic activity of PMN was determined by lactate production from glucose (Fig. 3) . In intact cells ofGSD lb patients (Fig. 3 B) , lactate production was 50% of that in controls (Fig.  3 A) . In the absence of glucose lactate production from the endogenous substrate, there was no difference between control and GSD lb patients (12±4 and 10.8 nmol/ 106 per h, respectively). In disrupted PMN, glycolytic activity in all groups was similar. In lymphocytes, the glycolytic activity of both GSD Ia and GSD lb patients did not differ from that in controls (data not shown).
As glycogen can serve as a substrate for lactic acid production, we measured glycogen concentrations in PMN of two GSD lb patients. Glycogen concentrations in A.A.'s and L.S.'s PMN were found to be 20 and 28 mg/106 cells, respectively, which is not significantly different from the glycogen concentration in control PMN: 25±7 mg/106 cells.
The reduced activity of both HMP shunt and glycolysis in intact PMN of GSD Tb patients could have been due to a reduction either in glucose transport into the cells or in the availability of cofactors such as ATP, NAD, or NADP. Fig. 4 shows that the transport of 2-deoxyglucose into control PMN was linear with time up to 5 min, and was almost completely inhibited by 10 mM glucose or 0.1 mM phloretin, indicating that 2-deoxyglucose competes with glucose for entry into the cell. 2-Deoxyglucose transport into F .
N. (Table IV) . As can be seen, there was no significant difference in the phosphorylation of deoxyglucose between the PMN of the control and the patient.
To examine whether the cells were intact, we tested their resistance to various osmotic pressures. As can be seen in Fig.  6 , the osmotic fragility ofthe PMN cells ofthe GSD Ib patients did not differ from that of the control.
Efflux of 2-deoxyglucose from loaded PMN was measured as described in Methods. The [3H]2-deoxyglucose lost from the cells was fully accounted for by its appearance in the efflux medium. Its appearance in the supernatant increased in approximate proportion to time through at least 20 min of incubation. Calculations of the velocity of 2-deoxyglucose efflux were based on samples obtained between 0 and 20 min of incubation. The rate of efflux of GSD lb PMN did not differ from those of control PMN (0.055 and 0.049 nmol/min per 106, respectively).
In an additional experiment, uptakes of 2-deoxyglucose, lactate, and CO2 production were assayed on PMN from the same blood sample. In accordance with previous results, 2-deoxyglucose transport into PMN of the patient was 30% of that of the control. Glycolytic rates and HMP activity were similarly reduced in the PMN ofGSD lb patients; there was no difference, however, in the relative contribution of CO2 and lactate production in cells from the patient and the control (Table V) . 
Discussion
The present study demonstrates an abnormal metabolism of PMN from patients with GSD lb, manifested by a reduction in activity of the HMP shunt, glycolysis, and glucose transport into the cells. The reduced activities in PMN of GSD lb patients could not be ascribed to differences in metabolic disturbances, such as recurrent hypoglycemia, lactic acidosis, or hyperuricemia, since glucose metabolism of PMN of GSD Ta patients did not differ from that of normal controls. Our study confirms previous observations on abnormal HMP shunt activity in PMN of GSD lb patients ( 11) and is in accordance with the results of Seger et al., who found a reduced oxygen burst during phagocytosis in whole cells, which was corrected by cell disruption and addition of NADPH (14). Seger (14) suggested that this reduced oxygen burst was due to a deficiency of NADPH in these cells. In the present study, NADPH levels were not measured, but low levels of NADPH cannot account for the reduced glycolytic activity; it is therefore unlikely that this could be the only defect in PMN from these patients. The present study shows that the metabolic defect in PMN of GSD lb patients is not limited to the HMP shunt. The primary defect seems to be a reduction in the availability of G6P, causing a quantitatively similar impairment in both glycolytic and HMP shunt activity. The production of G6P in the cell depends on (a) glucose transport, (b) availability of ATP, (c) activity of hexokinase, and (d) degradation of glycogen. In the present study, hexokinase activity and ATP concentration in cells of GSD Tb patients did not differ from those of controls, leaving a reduced transport of glucose into the cell as the most likely alternative, which was confirmed by 2-deoxyglucose transport studies.
Part of 2-deoxyglucose accumulates in the neutrophils in a phosphorylated form; thus, the amount of 2-deoxyglucose retained by the neutrophils is a function of both the transport system and of the phosphorylation step.
As is evident from Table IV , there was no reduction in the ratio of 2-deoxyglucose-6-phosphate to 2-deoxyglucose in the patients' PMN as compared with control PMN either in zero trans conditions (2 min of incubation) or in steady state conditions (20 min of incubation). Thus, the rate of phosphorylation of 2-deoxyglucose is probably not the cause for the reduction in 2-deoxyglucose transport into the patients' cells observed at different substrate concentrations, as is evident in Fig. 5 . However, one cannot exclude the possibility that the impairment of influx is secondary to a reduction in ATP concentrations in the presence of 2-deoxyglucose. Since glucose transport into the Tb neutrophils was diminished by 70%, the reduced production of C'402 through the HMP shunt could be due partly to the dilution of the radioactive G6P pool by cold G6P derived from endogenous glycogen. Yet such a dilution cannot explain the reduction in lactic acid production found in the patients' neutrophils (Fig. 3) . The reason for the enhanced shunt activity found in the patients' neutrophils during infections (Table III) is not yet clear. It may be a result of activation of the HMP shunt, activation of glucose transport, or changes in the neutrophil population during infection.
The diminished rates of deoxyglucose uptake into the lb PMN is probably not a reflection of a selected subpopulation of neutrophils, since transport of 2-deoxyglucose in PMN of a patient suffering from recurrent neutropenia was found to be within the normal range.
The diminished 2-deoxyglucose transport in the lb PMN seems to be a specific and not a generalized defect in the membrane itself, since the osmotic fragility, which is a crude index of membrane integrity, did not differ from that of the controls (Fig. 6) . Moreover, efflux of 2-deoxyglucose from loaded patient PMN was the same as in controls.
The relationship between the hepatic microsomal G6P translocase defect in the lb patients and the neutrophil glucose transport defect is not clear. Roles of the multifunctional G6Pase system in insulin-independent glucose transport in various tissues have been suggested (24, 25) . However, the possibility of a common subunit for glucose transport and microsomal G6P transport is unlikely, since in erythrocytes at least, the glucose transporter was found to be a single polypeptide (26).
A reduced transport of glucose into PMN can be due to a reduction in the number or activity of transporters. Synthesis of glucose transporters takes place in the endoplasmic reticulum (27) and may, in an unknown way, be directly dependent on the availability of microsomal G6P or indirectly on NADPH, a product of the microsomal hexose-6-phosphatedehydrogenase (28, 29) . A defect in the synthesis of glucose transporters could lead to a reduction in the number of transporters or to a change in properties, resulting in reduced transport capacity. The striking reduction in glucose transport observed in the PMNs of GSD lb patients could be responsible for the metabolic and functional deficiencies in these cells.
